Antifungal Treatment Market is Expected to Grow at a CAGR of 3.89% By 2030

The global antifungal treatment market is projected to register a CAGR of 3.89% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global antifungal treatment market Pfizer Inc (US), Johnson & Johnson Services, Inc (US), Bayer AG (Germany), Novartis AG (Switzerland), Abbott Laboratories, Inc. (US), Merck KGaA (Germany), Gilead Sciences, Inc (US), Cipla, Inc. (India), Sanofi S.A. (France), and GlaxoSmithKline Plc (UK).

Market Highlights

The global antifungal treatment market is accounted to register a CAGR of 3.89% during the forecast period and is estimated to reach USD 23.76 billion by 2032.

The growth of the anti-fungal treatment market is attributed to the increasing incidence of fungal infections, the increasing prevalence of immunological diseases, and the availability of a wide range of products. Fungal infections pose a significant threat to individuals with weakened immune systems, such as those living with human immunodeficiency virus (HIV)/ Acquired Immune Deficiency Syndrome (AIDS). As per the Joint United Nations Programme on HIV/AIDS (UNAIDS), there were approximately 39 million people living with HIV, globally. These individuals are more susceptible to opportunistic fungal infections, which can be challenging to treat and have potentially severe consequences. Furthermore, The Centers for Disease Control and Prevention (CDC) estimates that in the US alone, fungal diseases lead to over 75,000 hospitalizations and nearly 9 million outpatient visits annually. This highlights the widespread impact of fungal infections on public health.

However, voluntary product recalls from the market players are anticipated to hamper the global anti-fungal treatment market's growth. Moreover, the development of new drugs is creating lucrative growth opportunities for the global anti-fungal treatment market during the forecast period.

Access full report @ https://www.marketresearchfuture.com/reports/antifungal-treatment-market-1628

Segment Analysis

The global antifungal treatment market has been segmented based on drug class, route of administration, indication, pathogen, and end user.

On the basis of drug class, the global antifungal treatment market is segmented into azoles, echinocandins, polyenes, allylamines, pyrimidines, and others. The azoles segment accounted for the largest market with a market share of over 48% in 2022, and the polyenes segment is anticipated to be the fastest-growing for the forecast period of 2023–2032. The wide range of applications of drug classes, such as azoles, have a broad spectrum and are effective against a wide range of fungal infections; echinocandins are primarily used for serious invasive fungal infections; and polyenes are used for severe or life-threatening fungal infections, often intravenously. Furthermore, allylamine is primarily used for topical treatment of skin infections, such as athlete's foot and nail fungus, and pyrimidines are used in combination with other antifungals to treat specific fungal infections. Hence, the above-mentioned benefits of drug classes, which make each of them special, are fostering the growth of the market.

Based on route of administration, the global antifungal treatment market is segmented into oral, topical, and parenteral. The topical segment accounted for the largest share in 2022, and the parenteral segment was the fastest-growing segment during the forecast period. Topical treatments, applied directly to the infected area, boast ease of use, minimal systemic side effects, and targeted action. They're perfect for mild, localized infections like athlete's foot or nail fungus, promoting quick resolution and reducing the risk of drug resistance. Moreover, injectable or intravenous antifungals deliver a potent punch directly into the bloodstream, effectively battling severe or widespread infections that threaten internal organs. While they may carry a higher risk of side effects, their systemic action provides a crucial line of defense in critical situations. Hence, widespread utilization of both topical and parenteral products is propelling the growth of the administration segment.

The global antifungal treatment market, based on indication, is segmented into dermatophytosis, aspergillosis, candidiasis, invasive candidiasis, vulvovaginal candidiasis, mouth/throat/esophageal candidiasis, and others. The candidiasis segment accounted for the largest market with a market share of over 36% in 2022, owing to increasing incidences of candidiasis globally. Moreover, dermatophytosis registered the highest growth during the forecast period due to rising awareness of early diagnosis and the availability of advanced diagnostic techniques.

On the basis of pathogens, the global antifungal treatment market is segmented into candida, aspergillus, cryptococcus, coccidioides immitis, zygomycetes, trichophyton, and others. The candida segment accounted for the largest market in 2022, owing to its spread at an alarming rate in U.S. healthcare facilities in 2020–2021, as reported by the Centers for Disease Control and Prevention. Furthermore, cryptococcus is the fastest-growing segment during the forecast period because of increasing incidences of HIV/AIDS, as it is most common among HIV/AIDS patients. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 1.3 million people were newly infected with HIV in 2022.

Based on end users, the global antifungal treatment market is segmented into hospitals and clinics, dermatology clinics, and others. The dermatology clinics segment accounted for the largest share in 2022, and the hospitals & clinics segment was the fastest-growing segment during the forecast period. The factors positively influencing the growth of the end user segment are increasing awareness of innovative treatment among both patients and healthcare professionals, rising incidences of different types of fungal infections, and the growing collaboration of product manufacturers with hospitals and clinics to meet customer demands.

Regional Analysis

The global antifungal treatment market, based on region, has been divided into North America, Europe, Asia-Pacific, and Middle East & Africa. North America further includes the US and Canada. The Europe includes countries namely Germany, France, UK, Italy, Spain, and Rest of Europe. The global antifungal treatment market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and Rest of Asia-Pacific. Moreover, the rest of the world comprises of Middle East, Africa, and Latin America.

North America is a large antifungal treatment market due to the increasing number of people with fungal infections and forming strategies to distribute and sell antifungal medicine in the US. As per the Centers for Disease Control and Prevention, the cases of Candida were 1,171, 1,439, and 1,769 in 2019, 2020, and 2021, respectively.   Therefore, increasing incidences of fungal infection and rising demand for innovative products have led to the formation of strategic alliances, which are boosting the North America region’s market growth.

Moreover, Europe is predicted to develop significantly in the worldwide market due to increasing funding to develop antibiotic-free vaginal infections drug is creating an immense opportunity for the market in the region. For instance, in May 2023, Gedea Biotech (Sweden) raised USD 1.46 million for the additional development activities of its product, namely pHyph. This product has shown a clinical cure rate for bacterial vaginosis. Also, in April 2022, the European Centre for Disease Prevention and Control (ECDC) reported that Candida auris cases have been rising in European countries, mainly in Spain and Italy. In Spain, the cases were 260 in 2020 and increased to 331 in 2021; in Italy, 49 cases were in 2020 and 242 in 2021. Hence, increasing cases of fungal infections and fund-raising in order to fulfill European population demand are propelling the region’s market growth.

Furthermore, the Asia-Pacific region presents lucrative prospects for companies in the antifungal treatment market, owing to increasing fungal infection cases in Asian countries. Product launches to fulfill the growing need for anti-fungal disease treatment are boosting the region’s growth. For instance, in July 2020, Pfizer Inc. (US) launched the Cresemba, in Taiwan, and before one year, that is, in 2019, Cresemba had been launched in Australia. The Cresemba is a capsule that treats invasive aspergillosis and mucormycosis in adults. Hence, the increasing prevalence of fungus infections in Asian countries and product launches to meet the growing demand are bolstering the region’s market growth.

Additionally, the following regions: the Middle East, Africa, and Latin America are considered under the Rest of the World. The increasing incidence of fungus infections in South Africa is fostering the region’s market growth. The Global Action for Fungal Infections reported in 2019 that approximately 3.2 million South Africans get affected by fungal infections each year. Moreover, in patients suffering from the human immunodeficiency virus (HIV), there are huge chances of having a fungal infection, mostly reported in the Middle East and North Africa (MENA) region. Thus, the increasing prevalence of various fungal infections, the rising incidence of human immunodeficiency diseases, and favorable government support in providing licenses to sell anti-fungal drugs from outsiders are propelling the region’s growth.

Key Findings of the Study

• The global antifungal treatment market is expected to reach USD 23.76 billion by 2032 at a CAGR of 3.89% during the forecast period.


• The Europe region held the second largest market share of the global market, owing to a rising incidences of fungal infection, and a presence of major players.


• Based on indication, the candidiasis segment held the largest market in 2022 and dermatophytosis is the fastest growing segment during the forecast period.


• Pfizer Inc (US), Johnson & Johnson Services, Inc (US), Bayer AG (Germany), Novartis AG (Switzerland), Abbott Laboraotories, Inc. (US), Merck KGaA (Germany), Gilead Sciences, Inc (US), Cipla, Inc. (India), Sanofi S.A. (France), and GlaxoSmithKline Plc (UK) are the key players in the market.